Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DV3C | ISIN: US92536C1036 | Ticker-Symbol: FMW
Tradegate
30.06.25 | 21:41
0,511 Euro
+2,18 % +0,011
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VERU INC Chart 1 Jahr
5-Tage-Chart
VERU INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,4870,50208:23
0,4870,50208:03

Aktuelle News zur VERU Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
24.06.Why Veru Inc. Is Rising In Pre-market?10
24.06.Veru reports positive results for enobosarm in weight management study10
VERU Aktie jetzt für 0€ handeln
24.06.Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation187--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study...
► Artikel lesen
11.06.Veru Inc.: Veru to Participate in the Virtual BTIG Obesity Health Forum10
30.05.Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave13
30.05.Beyond Meat, PLBY Group among consumer staple names set to join Russell Microcap Index, Veru, Vitals Farms to leave37
28.05.Muscle-sparing obesity drug safe for Phase 3 trial, Veru says30
28.05.Veru's Enobosarm Shows Muscle In Wegovy Combo Trial53
28.05.Veru Inc.: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide ...203--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial...
► Artikel lesen
08.05.Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial35
08.05.VERU INC. - 10-Q, Quarterly Report2
08.05.JTC Team, LLC: JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s Enobosarm Taking GLP-1 Weight Loss to Next Level435Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru Watch the "KOL Connect" segment here FRENCHTOWN...
► Artikel lesen
08.05.Veru Inc.: Veru Participates in a Virtual Investor KOL Connect Segment6
08.05.VERU INC. - 8-K, Current Report3
08.05.Veru Inc.: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress559--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second...
► Artikel lesen
07.05.A Peek at Veru's Future Earnings7
07.05.Veru Q2 2025 Earnings Preview4
01.05.Veru Inc.: Veru to Report Fiscal 2025 Second Quarter Financial Results on May 88
16.04.Veru Inc.: Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit12
14.03.VERU INC. - 8-K, Current Report13
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,4